Magic mushrooms as a treatment for depression
Clinical pharmacist 2017 DOI: 10.1211/cp.2017.20204046 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Observational study Peer reviewed |
|---|---|
| Sample size | 19 |
| Population | Patients with treatment-resistant depression |
| Intervention | Psilocybin |
| Dose | two doses |
| Topics | Depression Psilocybin |
| Key findings | Psilocybin alters brain blood flow in patients with treatment-resistant depression, suggesting a potential mechanism for its antidepressant effects. |
Abstract
Psilocybin, a psychoactive component of magic mushrooms, is thought to have therapeutic potential in psychiatric disorders but its mechanism of action within the brain is unclear. In a study, researchers gave two doses of psilocybin to 19 patients with treatment-resistant depression, and studied blood flow within the brain using functional magnetic resonance imaging (MRI) at […]
Comparable studies
Other observational and cohort studies on psilocybin for depression, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. Patients with treatment-resistant depression | 2017 | Observational cohort | n = 19 |
| Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression Patients with treatment-resistant depression and healthy controls | 2017 | Observational cohort | n = 33 |
| More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression Patients with treatment-resistant depression (TRD) | 2018 | Observational cohort | n = 15 |
| Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. 17 patients with treatment-resistant depression and 18 untreated age-matched healthy... | 2018 | Observational cohort with machine learning classification | n = 35 |
| Brain dynamics predictive of response to psilocybin for treatment-resistant depression. Responders and non-responders to psilocybin therapy for depression | 2024 | Observational cohort |